Alyeska Investment Group L.P. Purchases New Shares in Nuvectis Pharma, Inc. $NVCT

Alyeska Investment Group L.P. acquired a new stake in shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 275,000 shares of the company's stock, valued at approximately $5,057,000. Alyeska Investment Group L.P. owned 0.84% of Nuvectis Pharma at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Stonepine Capital Management LLC bought a new position in Nuvectis Pharma in the 2nd quarter worth $735,600. Bank of America Corp DE bought a new stake in Nuvectis Pharma during the 2nd quarter valued at approximately $218,000. Legal & General Group Plc purchased a new position in shares of Nuvectis Pharma during the 2nd quarter worth approximately $31,000. BlackRock Inc. purchased a new position in shares of Nuvectis Pharma during the 2nd quarter worth approximately $18,414,000. Finally, Deutsche Bank AG purchased a new position in shares of Nuvectis Pharma in the 2nd quarter valued at approximately $310,000. 96.77% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Cantor Fitzgerald started coverage on Nuvectis Pharma in a research report on Monday, August 24th. They set an "overweight" rating for the company. Wall Street Zen raised shares of Nuvectis Pharma from a "sell" rating to a "hold" rating in a research report on Saturday, May 9th. HC Wainwright raised their target price on shares of Nuvectis Pharma from $13.00 to $39.00 and gave the company a "buy" rating in a research note on Monday, June 22nd. UBS Group set a $33.00 price objective on Nuvectis Pharma in a research report on Monday, July 6th. Finally, Loop Capital set a $40.00 price objective on Nuvectis Pharma in a research note on Tuesday. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Nuvectis Pharma has a consensus rating of "Moderate Buy" and a consensus price target of $36.25.

Nuvectis Pharma Stock Performance

Shares of NASDAQ NVCT opened at $23.06 on Wednesday. The firm's 50 day moving average price is $20.98 and its 200-day moving average price is $13.54. The company has a market cap of $752.68 million, a PE ratio of -17.60 and a beta of -0.26. Nuvectis Pharma, Inc. has a 52-week low of $5.55 and a 52-week high of $29.27.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.04). On average, analysts forecast that Nuvectis Pharma, Inc. will post -1.01 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Nuvectis Pharma news, major shareholder Marlio Charles Mosseri acquired 50,000 shares of Nuvectis Pharma stock in a transaction that occurred on Tuesday, June 30th. The stock was bought at an average cost of $18.32 per share, for a total transaction of $916,000.00. Following the acquisition, the insider owned 3,186,576 shares of the company's stock, valued at $58,378,072.32. This represents a 1.59% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Ron Bentsur purchased 12,500 shares of Nuvectis Pharma stock in a transaction dated Tuesday, June 30th. The stock was bought at an average price of $20.00 per share, with a total value of $250,000.00. Following the completion of the purchase, the chief executive officer directly owned 3,688,424 shares of the company's stock, valued at approximately $73,768,480. This trade represents a 0.34% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 28.55% of the company's stock.

Nuvectis Pharma Company Profile

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.

Want to see what other hedge funds are holding NVCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source